Jeffrey V. Matous, MD

home / authors / jeffrey-v-matous-md

Articles

$Data from the phase 1b MonumenTAL-2 trial support pomalidomide plus talquetamab as a promising treatment option in relapsed/refractory multiple myeloma, says Jeffrey Matous, MD.$

Pomalidomide Combo Shows Deep, Enduring Responses in R/R Multiple Myeloma

January 3rd 2024

Data from the phase 1b MonumenTAL-2 trial support pomalidomide plus talquetamab as a promising treatment option in relapsed/refractory multiple myeloma, says Jeffrey Matous, MD.

A panel of 4 experts on multiple myeloma seated at a long table

Key Takeaways on the Treatment of Patients With Relapsed/Refractory MM

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

November 28th 2023

The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.

Treatment Decision-Making in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

November 28th 2023

Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.

Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

November 21st 2023

The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.

MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

November 21st 2023

Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.

Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

November 14th 2023

Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.

Dosing Considerations for Bispecific Antibodies in MM

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

November 14th 2023

Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.

Recent Data on Bispecific Antibodies in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

November 7th 2023

A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.

Multiple Myeloma Treatment: Patient Profiles

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

November 7th 2023

The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.

Treatment Decision-Making in Early-Relapse MM

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

October 31st 2023

Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.

Recent Data in the Management of Early-Relapse Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

October 31st 2023

A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.

Unmet Needs and Future Perspectives in Multiple Myeloma Treatment

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 21st 2022

A look at the unmet needs and future directions of multiple myeloma treatment.

Novel Agents Under Investigation for Multiple Myeloma

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 21st 2022

Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.

$CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies$

CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 19th 2022

Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.

$BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment$

BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 19th 2022

An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.

$Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma$

Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma

Rafael Fonseca, MD;Krina K. Patel, MD;Caitlin Costello, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 19th 2022

A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.

Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 19th 2022

A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.

First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial

Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD;Rafael Fonseca, MD

April 4th 2022

A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.

Treatment Duration and Response to Induction Therapy in Transplant-Eligible NDMM

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 4th 2022

Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.

Choosing Between Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

March 25th 2022

A discussion on choosing between triplet or quadruplet induction therapy for transplant-eligible newly diagnosed multiple myeloma.

Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM: Focus on GRIFFIN and MASTER Trials

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

March 25th 2022

An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.

Transplant-Ineligible MM: Navigating Treatment Challenges

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 15th 2021

A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.

Counseling Patients With MM About Treatment Duration

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 13th 2021

Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.

Transplant-Ineligible MM: Reinitiating Therapy

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 8th 2021

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.

Transplant-Ineligible MM: Treating to Progression

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 6th 2021

The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.

Maintenance Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 1st 2021

Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.

Triplet Vs Doublet Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 29th 2021

Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.

Managing A Case of Newly-Diagnosed Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 24th 2021

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

Managing Adequate/Inadequate Treatment Response in MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 22nd 2021

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.

MRD Testing in Multiple Myeloma

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 17th 2021

Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.

1 2 >